These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26873053)

  • 1. Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation.
    Springer MJ; Ni Y; Finger-Baker I; Ball JP; Hahn J; DiMarco AV; Kobs D; Horne B; Talton JD; Cobb RR
    Vaccine; 2016 Mar; 34(12):1452-8. PubMed ID: 26873053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.
    Ball JP; Springer MJ; Ni Y; Finger-Baker I; Martinez J; Hahn J; Suber JF; DiMarco AV; Talton JD; Cobb RR
    PLoS One; 2017; 12(5):e0177310. PubMed ID: 28545100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.
    Velasquez LS; Shira S; Berta AN; Kilbourne J; Medi BM; Tizard I; Ni Y; Arntzen CJ; Herbst-Kralovetz MM
    Vaccine; 2011 Jul; 29(32):5221-31. PubMed ID: 21640778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
    Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
    Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
    Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
    Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.
    Hjelm BE; Kilbourne J; Herbst-Kralovetz MM
    Hum Vaccin Immunother; 2014; 10(2):410-6. PubMed ID: 24280723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
    Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.
    Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY
    Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
    Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
    J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
    Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice.
    Heinimäki S; Malm M; Vesikari T; Blazevic V
    J Immunol Res; 2018; 2018():3487095. PubMed ID: 29682589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice.
    Wang X; Ku Z; Dai W; Chen T; Ye X; Zhang C; Zhang Y; Liu Q; Jin X; Huang Z
    Vaccine; 2015 Oct; 33(43):5779-5785. PubMed ID: 26424606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.
    Kim SH; Chen S; Jiang X; Green KY; Samal SK
    J Virol; 2014 Sep; 88(17):9718-27. PubMed ID: 24920815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological Correlates of Protection against a GII.4 Norovirus.
    Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
    Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.
    Ramani S; Neill FH; Ferreira J; Treanor JJ; Frey SE; Topham DJ; Goodwin RR; Borkowski A; Baehner F; Mendelman PM; Estes MK; Atmar RL
    Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28249841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
    Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
    Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge.
    Van Noort A; Nelsen A; Pillatzki AE; Diel DG; Li F; Nelson E; Wang X
    Virol J; 2017 Apr; 14(1):76. PubMed ID: 28403874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
    Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM
    J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.